フロリダ州における脂肪肝の臨床試験
フロリダ州内の拠点で、脂肪肝に関する20件の研究が参加者を募集しています。
フロリダ州内の都市
- Miami16件の研究
- Orlando9件の研究
- Hialeah9件の研究
- Ocala8件の研究
- Cape Coral6件の研究
- Sarasota6件の研究
- West Palm Beach5件の研究
- Jacksonville5件の研究
- Brandon4件の研究
- Doral4件の研究
- Spring Hill4件の研究
- Homestead4件の研究
- The Villages3件の研究
- Boca Raton3件の研究
- Deltona3件の研究
- St. Petersburg3件の研究
- Gainesville3件の研究
- Kendall3件の研究
- Town 'n' Country3件の研究
- Lakeland3件の研究
- Melbourne3件の研究
公式研究テキスト（英語）
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Health Awareness, Inc, Jupiter
- Evolution Clinical Trials, Miami
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/29更新 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- University of Miami Health System, Miami
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Evolution Clinical Trials, Hialeah Gardens
- Health Awareness, inc., Jupiter
- Genoma Research Group, Inc., Miami
- 他2件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- K2 Medical Research WINTER GARDEN, Clermont
- K2 Medical Research - Daytona Beach, Daytona Beach
- Care Access - Delray Beach, Delray Beach
- 他20件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Bradenton
- Akero Clinical Study Site, Brandon
- Akero Clinical Study Site, Cutler Bay
- 他23件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- 他19件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Synergy Healthcare, Bradenton
- Synergy Healthcare, Bradenton
- Health Awareness, Inc., Jupiter
- 他6件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Brandon
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- 他15件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- 89bio Clinical Study Site, Gainesville
- 他15件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
- AdventHealth Translational Research Institute, Orlando
被験者募集中健康なボランティア歓迎
25歳〜55歳 · 全性別 · 2026/08/12更新 · NCT06993454A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Brandon
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami Lakes
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- 他20件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Miami
- GSK Investigational Site, Viera
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, Tampa
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/06/09更新 · NCT07358546A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Genoma Research Group, Inc, Miami
- Med Research of Florida, LLC, Miami
被験者募集中第1/2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/04/16更新 · NCT05648214Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Clinical Pharmacology of Miami, Miami
被験者募集中観察研究
18歳〜75歳 · 全性別 · 2025/08/14更新 · NCT07122700Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- University of Florida, Gainesville
被験者募集中第2相
21歳〜75歳 · 全性別 · 2025/04/04更新 · NCT04501406AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- AdventHealth Translational Research Institute, Orlando
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 全性別 · 2025/03/13更新 · NCT04807868ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。